Saiag, P., Robert, C., Grob, J., Mortier, L., Dereure, O., Lebbe, C., Mansard, S., Grange, F., Neidhardt, E., Lesimple, T., Machet, L., Bedane, C., Maillard, H., Dalac-Rat, S., Nardin, C., Szenik, A., Denden, A., & Dutriaux, C. (2021). efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. European journal of cancer, 154, 57–65. http://access.bl.uk/ark:/81055/vdc_100139915950.0x00003b